A

August Bioservices

US-based CDMO for end-to-end drug development

Production Scheduler

Full-Time
No salary listed
Mid
Bachelor's
Nashville, TN, USA
In Person
Operations & LogisticsProduction Planning & Scheduling

About the job

Requirements
  • A bachelor's degree in Supply Chain, Operations Management, Engineering, Life Sciences, or a related field, or an equivalent combination of education and experience.
  • At least 3 years of production scheduling or planning experience in pharmaceutical, biotech, or sterile/aseptic manufacturing.
  • Working knowledge of aseptic processing concepts, including isolators or RABS, cleanroom classifications, media fills, and autoclave cycles.
  • Experience with enterprise resource planning or advanced planning and scheduling systems such as SAP, Oracle, JDE, PlanetTogether, Kinaxis, or similar.
  • Strong Excel skills, including pivot tables and lookups, and experience with scheduling or Gantt tools.
  • A solid understanding of current Good Manufacturing Practices, batch record processes, and regulated manufacturing documentation.
  • The ability to manage multiple shifting priorities under time pressure.
  • The ability to communicate across functions and present schedule risks to operations leadership.
Responsibilities
  • Build and maintain rolling detailed production schedules across dispensing, compounding, filling lines, visual inspection, and packaging suites.
  • Sequence batches to minimize changeover time, cleaning and sanitization cycles, and gowning transitions while respecting product segregation.
  • Adjust schedules in real time for deviations, equipment downtime, material delays, quality-control hold times, or client priority changes, and communicate impacts promptly.
  • Model suite, equipment, and labor capacity constraints to identify bottlenecks.
  • Partner with Manufacturing and Engineering on preventive maintenance and calibration scheduling to minimize production disruption.
  • Flag capacity gaps or overbooking risks to leadership and propose mitigation options.
  • Align detailed schedules with the Master Production Schedule, demand plan, and client-committed delivery dates.
  • Coordinate with Warehouse and Materials Management to confirm raw material, component, and primary packaging availability before scheduled batches.
  • Work with Quality Assurance to sequence batch record issuance, in-process testing, and release timelines.
  • Support Client Services and Program Management with schedule visibility, risk communication, and root-cause input for schedule-adherence metrics.
  • Maintain accurate schedule data in the enterprise resource planning system.
  • Ensure batch numbers, lot genealogy, and campaign sequencing are correctly reflected across scheduling and quality systems.
  • Generate schedule-adherence, on-time-in-full, and utilization reports for operations reviews.
  • Support root-cause analysis for schedule misses and participate in corrective and preventive action activities related to planning and scheduling.
  • Operate within current Good Manufacturing Practices, data-integrity, and site standard operating procedure requirements, and complete required training.
  • Participate in Sales and Operations Planning and tiered daily-management meetings, providing schedule status and escalating risks.
Desired Qualifications
  • Contract Development and Manufacturing Organization experience is strongly preferred.

About the company

August Bioservices is a US-based CDMO offering end-to-end drug development and manufacturing from pre-clinical to commercial. It combines large-CDMO scale with a customer-focused hybrid model to serve startups and big pharma. It provides full development programs including research, development, testing, lab services, and sterile fill/finish under one integrated process, ensuring cGMP and FDA-quality standards. Its goal is to help clients bring safe, effective drugs to market efficiently through a seamless, integrated pathway.

Company Size

51-200

Company Stage

Series B

Total Funding

$88.6M

Headquarters

Nashville, Tennessee

Founded

2017

Get referred to August Bioservices

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vial filling qualified in July 2026, unlocking throughput from the $60 million expansion.
  • Series B funding in 2025 financed an additional high-speed vial suite and automation.
  • August Bioservices' 2026 event calendar signals active business development across BIO, CPHI, and Contract Pharma.

What critics are saying

  • Sterile injectable capacity takes roughly 30 months to qualify, delaying revenue from expansion.
  • A single FDA contamination finding can halt lines, erase customer trust, and trigger recalls.
  • Specialization in sterile injectables concentrates exposure if outsourcing demand shifts or major clients leave.

What makes August Bioservices unique

  • Nashville campus offers sterile injectables, development, and manufacturing on one contiguous site.
  • August Bio runs fully isolated vial, syringe, and IV bag lines with in-house analytics.
  • The 2026 site integrates automated inspection, labeling, packaging, and serialization for faster releases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-2%
Business Wire
Sep 16th, 2026
August Bioservices Closes $23.6 Million Series A Extension to Expand U.S. Biopharma Manufacturing Capabilities

August Bioservices,LLC, a contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing ...

Pattern of USA
Sep 10th, 2026
Impact of August Biopharmaceutical Layoffs: Over 500 Jobs Lost, Marking a 90% Decrease Compared to the Previous Year

Impact of August Biopharmaceutical Layoffs: Over 500 Jobs Lost, Marking a 90% Decrease Compared to the Previous Year 09/10/2026

The Healthcare Technology Report
Mar 18th, 2026
Jenn Adams named Healthcare Technology CEO of the Year.

Jenn Adams named Healthcare Technology CEO of the Year. Published. March 18, 2026 At this year's NYC Awards Night, The Healthcare Technology Repo had the privilege of recognizing several exceptional leaders advancing innovation across healthcare technology. Congratulations to Jenn Adams, CEO of August Bioservices, on being named Healthcare Technology CEO of the Year. Jenn has led August Bioservices since its founding in 2020, building a contract development and manufacturing organization (CDMO) dedicated to sterile injectable therapies. Headquartered in Nashville, the company provides development and manufacturing services that help drug developers advance innovative therapies from early development through commercialization. Accepting the award, Jenn shared: "When we started our company five and a half years ago, we had a really clear goal and we set out to build a CDMO focused on sterile injectables that could truly serve as a partner to our clients, providing deep technical expertise and a state-of-the-art facility and equipment - all designed to help advance innovative therapies through development and commercialization. Our aspiration is to show up so fully for our clients that they cannot tell the difference anymore. It's indistinguishable to them who is on their team and who is on our team because we're working shoulder to shoulder to make sure the drug is advanced. And then we're bridging the innovation and bringing it to patients who need that innovation in the form of therapies." Please join The Healthcare Technology Repo in congratulating Jenn Adams on this well-deserved recognition. Picture: Jenn Adams speaks at NYC Awards Night

Teknovation.biz
Dec 13th, 2024
Tennessee Emerges As A Leading State For Bioscience R&D

A new report from the Biotechnology Innovation Organization (BIO) and TEConomy Partners LLC finds Tennessee has emerged as a leading state for bioscience research and development, with bioscience RD accounting... The post Tennessee emerges as a leading state for bioscience RD appeared first on Teknovation.biz.

Teknovation.biz
Jun 30th, 2024
News & Notes | Ut Research Foundation Welcomes Four Interns

Like this story? Please share!News & Notes | UT Research Foundation welcomes four interns ETSU's Innovation Lab Director Dr. Audrey Depelteau served as a judge at last week's 2024 SelectUSA Investment Summit.From Knoxville:To promote the commercialization of University of Tennessee (UT) innovations and to help train the next generation of commercialization professionals, the UT Research Foundation (UTRF) recently welcomed three new interns and one returning intern across its Knoxville and Memphis offices.In Knoxville, Andrea Gutierrez-Cortez and Lauren Williams , rising second-year law students at UT, Knoxville (UTK), joined the team as Commercialization Analysts. Jacob Hale is returning for his second year with UTRF as a Senior Commercialization Analyst. Hale is a rising third-year law student, while Gutierrez-Cortez completed her bachelor’s degree in human biology at the University of California, San Diego, and Williams majored in biomedical engineering at UTK.and , rising second-year law students at UT, Knoxville (UTK), joined the team as Commercialization Analysts. is returning for his second year with UTRF as a Senior Commercialization Analyst. Hale is a rising third-year law student, while Gutierrez-Cortez completed her bachelor’s degree in human biology at the University of California, San Diego, and Williams majored in biomedical engineering at UTK